Use of monoclonal antibodies in drug therapy for

Abstract

The paper gives the results of international studies of a role of targeted therapy for disseminated colorectal cancer (DCRC). It considers three drugs from this group - cetuximab (erbitux), panitumumab (vectibix), and bevacizumab (avastin). Erbitux demonstrated its activity against DCRC with EGFR receptor hyperexpression and KRAS wide-type and its ability to potentiate the antitumor activity of irinotecan. In DCRC patients without K-RAS mutation, the use of vectibix could significantly increase objective response rates, disease stabilization, and survival to progression as compared with the similar parameters during symptomatic therapy. Avastin therapy leads to a reduction in tumor growth and increases in overall survival (to 25 months) time to disease progression (by 20-25%) as compared to chemotherapy only.

Keywords

disseminated colorectal cancer / targeted therapy / monoclonal antibodies / cetuximab / panitumumab / bevacizumab

References

[1] Amado R., Wolf M., Peeters M. et al. // J. Clin. Oncol. - 2008. - Vol. 26. - P. 1626-1634.

[2] Avastin Package Insert. - San Francisco: Genentech; 2004 Feb.

[3] Bouganim N., Kavan P., Eid M. et al. // J. Clin. Oncol. - 2009. - Vol. 27 (suppl.). - Abstr. 5027.

[4] Bokemeyer C., Bondarenko I., Hartmann J. T. et al. // J. Clin. Oncol. - 2008. - Vol. 26 (suppl.). - Abstr. 4000.

[5] Cunningham D., Humblet Y. et al. // N. Engl. J. Med. - 2004. - Vol. 351. - P. 337-345.

[6] Damjanov N., Meropol N. J. Oncology. - 2004. - P. 479-503.

[7] Douillard J., Siena S., Cassidy J. et al. // Eur. J. Cancer. - 2009. - Vol. 7, N 3 (suppl.). - Abstr. 10LBA.

[8] Folprecht G. et al. // ASCO GI Symposium. - 2004. - Abstr. 283.

[9] Giantonio B. J., Catalano P. J., Meropol N. J. et al. // Proc. Am. Soc. Clin. Oncol. - 2005. - Vol. 23. - P. 259s. - Abstr. 2.

[10] Hochster H. S., Welles L., Hart L. et al. // Proc. Am. Soc. Clin. Oncol. - 2005. - Vol. 23. - P. 259s. - Abstr. 3515.

[11] Hurwitz H., Fehrenbacher L., Hainsworth J. et al. // Gastrointestinal Cancers Symposium. - San Francisco, 2004. - P. 182. - Abstr. 286.

[12] Hurwitz H., Fehrenbacher L., Novotny W. et al. // N. Engl. J. Med. - 2004. - Vol. 350. - P. 2335-2342.

[13] Jain R. K. // Nat. Med. - 2001. - Vol. 7. - P. 987-989.

[14] Kabbinavar F. et al. // J. Clin. Oncol. - 2003. - Vol. 21. - P. 60-65.

[15] Lenz H. J., Mayer R. J. et al. // J. Clin. Oncol. - 2005. - Vol. 23 (16s). - Abstr. 3536.

[16] Peeters M., Price T., Hotko Y. et al. // Eur. J. Cancer. - 2009. - Vol. 7, N 3. (suppl.). - Abstr. 14LBA.

[17] Presta L. G. et al. // Cancer Res. - 1997. - Vol. 57. - P. 4593-4599.

[18] Prewett M. et al. // Clin. Cancer Res. - 2002. - Vol. 8. - P. 994-1003.

[19] Rosenberg M. et al. // Symposium ASCO. - 2002. - Abstr. 536.

[20] Rougier P. et al. // J. Clin. Oncol. - 2004. - Vol. 22 (14s). - Abstr. 3513.

[21] Saltz L. B., Cox J. V., Blanke C. et al. // N. Engl. J. Med. - 2000. - Vol. 343. - P. 905-914.

[22] Saltz L., Meropol N. J. et al. // J. Clin. Oncol. - 2004. - Vol. 22. - P. 1201-1208.

[23] Saltz L., Lenz H., Hochster H. et al. // Proc. Am. Soc. Clin. Oncol. - 2005. - Vol. 23. - P. 259s. - Abstr. 3508.

[24] Saltz L., Clarke S., Diaz-Rubio E. et al. // J. Clin. Oncol. - 2007. - Vol. 25 (18s; suppl.). - Abstr. 4028.

[25] Souglakos J., Kalykaki A. et al. // Ann. Oncol. - 2006. - Vol. 17, N 1. - P. 1-6.

[26] Van Cutsem E. et al. // Ann. Oncol. - 2004. - Vol. 15 (suppl. 3). - Abstr. 339P.

[27] Van Cutsem E., Nowacki M. et al. // ASCO. - 2007. - Abstr. 4000.

[28] Van Cutsem E., Peeters M., Siena S. et al. // J. Clin. Oncol. - 2007. - Vol. 25. - P. 1658-1664.

[29] Wein A. et al. // Ann. Oncol. - 2001. - Vol. 12. - P. 1721- 1727.

[30] Wildiers H., Guetens G., De Boeck G. et al. // Br. J. Cancer. - 2003. - Vol. 88. - P. 1979-1986.

RIGHTS & PERMISSIONS

Eco-Vector